The latest price target for Inovio Pharmaceuticals (NASDAQ:INO) was reported by Piper Sandler on November 14, 2025. The analyst firm set a price target for $6.00 expecting INO to rise to within 12 months (a possible 281.90% upside). 5 analyst firms have reported ratings in the last year.

The latest analyst rating for Inovio Pharmaceuticals (NASDAQ:INO) was provided by Piper Sandler, and Inovio Pharmaceuticals reiterated their overweight rating.

The last upgrade for Inovio Pharmaceuticals Inc happened on January 25, 2024 when Oppenheimer raised their price target to $4. Oppenheimer previously had a perform for Inovio Pharmaceuticals Inc.

There is no last downgrade for Inovio Pharmaceuticals.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Inovio Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Inovio Pharmaceuticals was filed on November 14, 2025 so you should expect the next rating to be made available sometime around November 14, 2026.

While ratings are subjective and will change, the latest Inovio Pharmaceuticals (INO) rating was a reiterated with a price target of $5.00 to $6.00. The current price Inovio Pharmaceuticals (INO) is trading at is $1.57, which is out of the analyst’s predicted range.